[go: up one dir, main page]

WO2013117751A3 - Methods related to treatment of inflammatory diseases and disorders - Google Patents

Methods related to treatment of inflammatory diseases and disorders Download PDF

Info

Publication number
WO2013117751A3
WO2013117751A3 PCT/EP2013/052629 EP2013052629W WO2013117751A3 WO 2013117751 A3 WO2013117751 A3 WO 2013117751A3 EP 2013052629 W EP2013052629 W EP 2013052629W WO 2013117751 A3 WO2013117751 A3 WO 2013117751A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
treatment
inflammatory diseases
methods related
inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2013/052629
Other languages
French (fr)
Other versions
WO2013117751A2 (en
Inventor
Klaus Steensgaard FREDERIKSEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Priority to KR1020147022156A priority Critical patent/KR20140124767A/en
Priority to CA2864133A priority patent/CA2864133A1/en
Priority to BR112014019274A priority patent/BR112014019274A2/en
Priority to MX2014009490A priority patent/MX2014009490A/en
Priority to AU2013217940A priority patent/AU2013217940A1/en
Priority to CN201380019432.0A priority patent/CN104204230A/en
Priority to EP13704081.2A priority patent/EP2812445A2/en
Publication of WO2013117751A2 publication Critical patent/WO2013117751A2/en
Publication of WO2013117751A3 publication Critical patent/WO2013117751A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to gene markers associated with a method for predicting the clinical response in a patient suffering from an inflammatory diseases or disorders to an anti-inflammatory treatment.
PCT/EP2013/052629 2012-02-10 2013-02-11 Methods related to treatment of inflammatory diseases and disorders Ceased WO2013117751A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
KR1020147022156A KR20140124767A (en) 2012-02-10 2013-02-11 Methods related to treatment of inflammatory diseases and disorders
CA2864133A CA2864133A1 (en) 2012-02-10 2013-02-11 Methods related to treatment of inflammatory diseases and disorders
BR112014019274A BR112014019274A2 (en) 2012-02-10 2013-02-11 methods related to the treatment of inflammatory diseases and disorders
MX2014009490A MX2014009490A (en) 2012-02-10 2013-02-11 Methods related to treatment of inflammatory diseases and disorders.
AU2013217940A AU2013217940A1 (en) 2012-02-10 2013-02-11 Methods related to treatment of inflammatory diseases and disorders
CN201380019432.0A CN104204230A (en) 2012-02-10 2013-02-11 Methods related to treatment of inflammatory diseases and disorders
EP13704081.2A EP2812445A2 (en) 2012-02-10 2013-02-11 Methods related to treatment of inflammatory diseases and disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP12154917.4 2012-02-10
EP12154917 2012-02-10
US201261597924P 2012-02-13 2012-02-13
US61/597,924 2012-02-13

Publications (2)

Publication Number Publication Date
WO2013117751A2 WO2013117751A2 (en) 2013-08-15
WO2013117751A3 true WO2013117751A3 (en) 2013-10-03

Family

ID=48948117

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2013/052629 Ceased WO2013117751A2 (en) 2012-02-10 2013-02-11 Methods related to treatment of inflammatory diseases and disorders

Country Status (8)

Country Link
EP (1) EP2812445A2 (en)
KR (1) KR20140124767A (en)
CN (1) CN104204230A (en)
AU (1) AU2013217940A1 (en)
BR (1) BR112014019274A2 (en)
CA (1) CA2864133A1 (en)
MX (1) MX2014009490A (en)
WO (1) WO2013117751A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102481305B1 (en) 2016-05-20 2022-12-26 세다르스-신나이 메디칼 센터 Diagnosis of inflammatory bowel disease based on genes
CN110244053B (en) * 2019-05-09 2022-03-11 北京大学第三医院（北京大学第三临床医学院） Molecular marker for diagnosing lupus nephritis and pulmonary hypertension disease and application thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007006858A2 (en) * 2005-07-12 2007-01-18 Oy Jurilab Ltd Method for treatment of cardiovascular and metabolic diseases and detecting the risk of the same
WO2008048986A2 (en) * 2006-10-17 2008-04-24 Children's Hospital Medical Center Gene array technique for predicting response in inflammatory bowel diseases
WO2008104608A1 (en) * 2007-03-01 2008-09-04 Universite Catholique De Louvain Method for the determination and the classification of rheumatic conditions
WO2008157282A1 (en) * 2007-06-18 2008-12-24 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
WO2010113096A1 (en) * 2009-03-30 2010-10-07 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods of predicting clinical course and treating multiple sclerosis
US20110091457A1 (en) * 2009-10-16 2011-04-21 Cornelis Lammert Verweij Method for prognosticating the clinical response of a patient to b-lymphocyte inhibiting or depleting therapy
WO2011154139A2 (en) * 2010-06-07 2011-12-15 Roche Diagnostics Gmbh Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045261A2 (en) 1999-12-07 2001-06-21 Parthus Technologies Plc Model for charge pump phase-locked loop
EP1616575B1 (en) 1999-12-23 2012-06-06 ZymoGenetics, Inc. Method for treating inflammation
DE10227527A1 (en) 2002-06-20 2004-01-08 Clariant Gmbh Process for the preparation of disazo pigments
US7435800B2 (en) 2003-05-23 2008-10-14 Chi-Mei Medical Center Antibodies to interleukin-20 and method for inhibiting interleukin-20 induced cell proliferation
WO2005052000A2 (en) 2003-11-21 2005-06-09 Zymogenetics, Inc. Anti-il-20 antibodies and binding partners and methods of using in inflammation
IES20050495A2 (en) 2005-07-20 2006-11-01 Minroc Techn Promotions Ltd A drill bit assembly for fluid-operated percussion drill tools
WO2007038501A2 (en) 2005-09-27 2007-04-05 The Feinstein Institute For Medical Research Rheumatoid arthritis markers
WO2007081465A2 (en) 2005-12-09 2007-07-19 Chi-Mei Medical Center Antibodies to interleukin-20 and method for inhibiting interleukin-20 induced cell proliferation
EP1857559A1 (en) 2006-05-16 2007-11-21 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for predicting responsiveness to TNF alpha blocking agents
CA2668955A1 (en) 2006-11-09 2008-05-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for predicting therapeutic responsiveness to tnf-alpha blocking agents
WO2008132176A2 (en) 2007-04-27 2008-11-06 Universite Catholique De Louvain Method for evaluating the response of an individual to tnf blocking therapy
KR20100037590A (en) 2007-06-08 2010-04-09 바이오겐 아이덱 엠에이 인코포레이티드 Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
CA2728685A1 (en) 2008-06-30 2010-01-07 Novo Nordisk A/S Anti-human interleukin-20 antibodies
EP2337799A2 (en) 2008-08-28 2011-06-29 Wyeth LLC Uses of il-22, il-17, and il-1 family cytokines in autoimmune diseases
CA2752648A1 (en) 2009-03-05 2010-09-10 Abbott Laboratories Il-17 binding proteins
RU2539112C2 (en) 2009-09-03 2015-01-10 Дженентек, Инк. Methods of treating, diagnosing and monitoring of rheumatoid arthritis

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007006858A2 (en) * 2005-07-12 2007-01-18 Oy Jurilab Ltd Method for treatment of cardiovascular and metabolic diseases and detecting the risk of the same
WO2008048986A2 (en) * 2006-10-17 2008-04-24 Children's Hospital Medical Center Gene array technique for predicting response in inflammatory bowel diseases
WO2008104608A1 (en) * 2007-03-01 2008-09-04 Universite Catholique De Louvain Method for the determination and the classification of rheumatic conditions
WO2008157282A1 (en) * 2007-06-18 2008-12-24 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
WO2010113096A1 (en) * 2009-03-30 2010-10-07 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods of predicting clinical course and treating multiple sclerosis
US20110091457A1 (en) * 2009-10-16 2011-04-21 Cornelis Lammert Verweij Method for prognosticating the clinical response of a patient to b-lymphocyte inhibiting or depleting therapy
WO2011154139A2 (en) * 2010-06-07 2011-12-15 Roche Diagnostics Gmbh Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
JULIÀ ANTONIO ET AL: "Identification of candidate genes for rituximab response in rheumatoid arthritis patients by microarray expression profiling in blood cells", PHARMACOGENOMICS, FUTURE MEDICINE LTD, UK, vol. 10, no. 10, 1 October 2009 (2009-10-01), pages 1697 - 1708, XP009160425, ISSN: 1744-8042 *
LEQUERRÉ THIERRY ET AL: "Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis", ARTHRITIS RESEARCH AND THERAPY, BIOMED CENTRAL, LONDON, GB, vol. 8, no. 4, 3 July 2006 (2006-07-03), pages R105, XP021020585, ISSN: 1478-6354, DOI: 10.1186/AR1924 *
NAKADA S ET AL: "Identification of candidate genes involved in endogenous protection mechanisms against acute pancreatitis in mice", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 391, no. 3, 15 January 2010 (2010-01-15), pages 1342 - 1347, XP026854448, ISSN: 0006-291X, [retrieved on 20100114], DOI: 10.1016/J.BBRC.2009.12.047 *
SARCHIELLI P ET AL: "Fibroblast growth factor-2 levels are elevated in the cerebrospinal fluid of multiple sclerosis patients", NEUROSCIENCE LETTERS, LIMERICK, IE, vol. 435, no. 3, 25 April 2008 (2008-04-25), pages 223 - 228, XP022655800, ISSN: 0304-3940, [retrieved on 20080226], DOI: 10.1016/J.NEULET.2008.02.040 *
SEKIGUCHI N ET AL: "Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab", RHEUMATOLOGY, OXFORD UNIVERSITY PRESS, LONDON, GB, vol. 47, no. 6, 1 June 2008 (2008-06-01), pages 780 - 788, XP002562468, ISSN: 1462-0324, DOI: 10.1093/RHEUMATOLOGY/KEN083 *
SIRPA LEIVO-KORPELA ET AL: "Adipokine resistin predicts anti-inflammatory effect of glucocorticoids in asthma", JOURNAL OF INFLAMMATION, vol. 8, no. 1, 1 January 2011 (2011-01-01), pages 12, XP055030042, ISSN: 1476-9255, DOI: 10.1186/1476-9255-8-12 *
TANINO M ET AL: "Prediction of efficacy of anti-TNF biologic agent, infliximab, for rheumatoid arthritis patients using a comprehensive transcriptome analysis of white blood cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 387, no. 2, 18 September 2009 (2009-09-18), pages 261 - 265, XP026434615, ISSN: 0006-291X, [retrieved on 20090703], DOI: 10.1016/J.BBRC.2009.06.149 *

Also Published As

Publication number Publication date
WO2013117751A2 (en) 2013-08-15
CA2864133A1 (en) 2013-08-15
CN104204230A (en) 2014-12-10
AU2013217940A1 (en) 2014-07-31
EP2812445A2 (en) 2014-12-17
MX2014009490A (en) 2014-08-29
BR112014019274A2 (en) 2017-06-27
KR20140124767A (en) 2014-10-27

Similar Documents

Publication Publication Date Title
WO2012149299A3 (en) Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
EP2710370A4 (en) Methods of diagnosing and treating pulmonary diseases or disorders
GB2492487B (en) Cannabinoids for use in the treatment of neurodegenerative diseases or disorders
LT2796132T (en) NEUROLOGICAL DISORDERS THERAPY ON THE BASIS OF BACLOFEN AND ACAMPLE
ZA201504484B (en) Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
TWI560200B (en) Anti-kir antibodies for the treatment of inflammatory and autoimmune disorders
LT2726511T (en) COMPOSITIONS, USES AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS AND DISEASES
EP2621499A4 (en) Methods for the treatment of allergic diseases
WO2011140517A9 (en) Methods for treating diseases of the lung
WO2014004990A3 (en) Methods for determining drug efficacy using cereblon-associated proteins
WO2014055790A9 (en) Methods and processes for non-invasive assessment of genetic variations
EP2663653A2 (en) Methods for diagnosing and treating eye-length related disorders
WO2014200952A3 (en) Genetic markers of antipsychotic response
EP3039431A4 (en) Method of identifying biomarkers of neurological diseases and diagnosis of neurological diseases
AP2014007804A0 (en) Compositions and methods for the treatment of hepatic diseases and disorders.
HUE036248T2 (en) Aminoglycosides and their applications for the treatment of genetic disorders
WO2013023059A3 (en) Methods and compositions for the treatment of autoimmune and inflammatory diseases
IL232710B (en) l-serine preparations, methods and uses for the treatment of neurodegenerative diseases and disorders
EP3052137A4 (en) Methods for the identification, assessment, prevention, and treatment of neurological disorders and diseases using fndc5
IL238415A0 (en) Compositions and methods for treating or preventing diseases or disorders associated with misregulated eif4e
WO2013117751A3 (en) Methods related to treatment of inflammatory diseases and disorders
WO2011143557A3 (en) Humanized ttc and methods of use thereof
HK1250176A1 (en) Biomarkers for determining the clinical response to cell therapy
WO2011139368A3 (en) Methods of treatment of inflammatory diseases
WO2012166659A3 (en) Anti-emr1 antibodies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13704081

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2013704081

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2013217940

Country of ref document: AU

Date of ref document: 20130211

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2014/009490

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 20147022156

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2864133

Country of ref document: CA

Ref document number: 2014556088

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2014135733

Country of ref document: RU

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014019274

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014019274

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140805